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AbstrACt
Introduction Cleft palate is among the most common 
birth abnormalities. The success of primary surgery in 
the early months of life is crucial for successful feeding, 
speech, hearing, dental development and facial growth. 
Over recent decades, age at palatal surgery in infancy 
has reduced. This has led to palatal closure in one-stage 
procedures being carried out around the age of 12 months, 
but in some cases as early as 6 months. The primary 
objective of the Timing Of Primary Surgery for Cleft Palate 
(TOPS)trial is to determine whether surgery for cleft palate 
performed at 6 or 12 months of age is most beneficial for 
speech outcomes.
Methods and analysis Infants with a diagnosis of 
non-syndromic isolated cleft palate will be randomised 
to receive standardised primary surgery (Sommerlad 
technique) for closure of the cleft at either 6 months or 
12 months, corrected for gestational age. The primary 
outcome will be perceived insufficient velopharyngeal 
function at 5 years of age. Secondary outcomes measured 
across 12 months, 3 years and 5 years will include growth, 
safety of the procedure, dentofacial development, speech, 
hearing level and middle ear function. Video and audio 
recordings of speech will be collected in a standardised 
age-appropriate manner and analysed independently 
by multiple speech and language therapists. The trial 
aims to recruit and follow-up 300 participants per arm. 
Data will be analysed according to the intention-to-treat 
principle using a 5% significance level. All analyses will be 
prespecified within a full and detailed statistical analysis 
plan.
Ethics and dissemination Ethical approval has been 
sought in each participating country according to country-
specific procedures. Trial results will be presented at 
conferences, published in peer-reviewed journals and 
disseminated through relevant patient support groups.
trial registration number NCT00993551; Pre-results.
IntroduCtIon
Clefts of the lip and/or palate, occurring with 
an incidence of about 1 per 600 births, are 
among the most common birth anomalies. 
This trial will focus on isolated clefts of 
the palate, which occur with a global inci-
dence of 4.5 per 10 000 births.1 Depending 
on geographic location, the prevalence of 
isolated clefts of the palate ranges from 1.8 to 
14.6 per 10 000.1 
The timing of palatal surgery has been a 
controversial issue since the 1930s.2 Tradition-
ally, rationale for delaying hard palate surgery 
was partly based on the belief that postponing 
the trauma of palatal closure may reduce 
maxillary growth disturbance. However, there 
is little evidence that facial skeletal growth in 
individuals with isolated cleft palate is substan-
tially affected by different surgical protocols, 
though maxillary arch form, especially trans-
versely, may be affected.3–6
Over recent decades, the age at which 
palatal surgery is carried out has reduced. 
This has led to one-stage palatal closure within 
12 months of age at cleft units in Europe and 
the USA. Protagonists of early closure of the 
strengths and limitations of this study
 ► International trial covering speech development in 
children across Scandinavia, the UK and Brazil.
 ► Surgical repair was calibrated across surgeons who 
were all trained in the Sommerlad technique.
 ► Longitudinal speech assessments at 12 months, 3 
years and 5 years will be independently analysed by 
multiple speech and language therapists whose rat-
ings will be calibrated on practice recordings.
 ► Standardised assessments of additional outcomes 
include postoperative complications, hearing levels, 
middle ear function and dentofacial development.
 ► The study excludes coexisting conditions such as 
syndromic cleft palate or severe developmental de-
lays that are known to adversely affect speech de-
velopment or its assessment.
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palatal cleft have proposed that since speech is a learnt 
behaviour, the sooner an intact anatomy is created, the 
better.7–10 As yet, however, there is no evidence that early 
surgery would lead to better speech development.
rationale
The widespread uncertainty surrounding the timing of 
palatal closure is reflected in the diversity of protocols 
currently employed by the Scandcleft Research Group, a 
partnership of Scandinavian and UK cleft lip and palate 
centres.11–22 The Scandcleft Research Group identified 
this uncertainty as a priority research question for a future 
trial. Its aim was to determine whether, in infants with cleft 
palate, repair at either age 6 or 12 months (corrected for 
gestational age) would achieve better speech outcomes. 
The design of the trial was supported by a planning grant 
from the National Institute of Dental and Craniofacial 
Research (NIDCR), a substream of the US National Insti-
tutes of Health (NIH), who subsequently funded the 
proposed trial.
objectives
The aim of this project is to determine whether, in infants 
with isolated cleft palate, it is better to perform primary 
surgery at age 6 or 12 months (corrected for gestational 
age). Gestational age will be assessed based on the date 
of the last menstrual period and the infant’s date of birth 
(full term defined as day 1 of the 40th week of preg-
nancy), thus taking account of prematurity. This research 
will investigate the effect of the timing of surgery by 
assessing and comparing speech development outcomes 
measured across 12 months, 3 years and 5 years of age. 
In addition, secondary outcomes include growth, periop-
erative complications, dentofacial development, hearing 
level and middle ear function.
MEthods And AnAlysIs
design
Timing Of Primary Surgery for cleft palate (TOPS) is an 
international, multisite trial using a parallel arm design 
aiming to detect whether surgery at 6 months is supe-
rior to surgery at 12 months. Infants will be randomised 
to receive primary surgery for cleft palate using a stan-
dardised technique (the Sommerlad technique)23 at 
either age 6 or 12 months (corrected for gestational age). 
The study design of TOPS trial is illustrated in figure 1.
setting
The trial will be conducted by the cleft palate teams based 
in centres across the UK, Scandinavia and Brazil. Criteria 
for selection of sites are based primarily on the ability to 
enrol a high volume of patients into the trial. A list of the 
TOPS trial sites is provided in table 1. The cleft team at 
each centre generally includes cleft surgeon(s), nursing 
staff, cleft speech and language therapist(s) (SLT), clin-
ical geneticist(s)/paediatrician(s), audiologist(s), ortho-
dontist(s) and psychologist(s)/social worker(s).
Eligibility criteria
All infants referred to the participating specialised cleft 
lip and palate centres are eligible to enter the trial if they 
meet the following inclusion and none of the exclusion 
criteria:
a. Isolated cleft palate.
b. Medically fit for surgery at 6 months, corrected for ges-
tational age.
c. Written informed proxy consent.
d. One parent/carer must be a native language speaker 
of the majority language in the country of residence.
Infants with any of the following will be excluded from 
the study:
a. Consent not obtained.
b. Infants with severe developmental delay (as measured 
on DENVER II) or syndromic cleft palate (except Van 
der Woude syndrome, which can be included if hear-
ing is not affected) will be excluded.
c. Congenital sensorineural hearing loss or structural 
middle ear anomalies.
d. Sommerlad technique could not be performed due to 
variation in the anatomical presentation.
e. Infants presenting with submucous cleft palate (de-
fined by the classical triad of signs, bifid uvula, bony 
defect of the hard palate, muscular diastasis, as de-
scribed by Jensen et al24).
f. Where the language spoken at home by at least one 
parent is not the majority language in the country of 
residence.
Since not all syndromic disorders will present prior to 
recruitment, all participants will undergo genetic testing 
to exclude chromosome abnormalities at the time of 
surgery. If a chromosome abnormality or another genetic 
syndrome is identified later in the study, the data for these 
participants will be handledas appropriate and in accord-
ance with the presepecified Statistical Analysis Plan. The 
same will apply if the participant fails the DENVER II 
developmental test at 3-year follow-up.
Figure 1 Flow diagram of Timing Of Primary Surgery for 
cleft palate study design.
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Consent
Informed consent will be sought from the infant’s 
parent/guardian by a member of the local trial team. 
Families who decline to participate will receive surgery in 
line with the hospital’s current practice together with the 
same level of care and support as families participating 
in the trial. Consent forms used in the TOPS trial in the 
UK are shown in online supplementary materials nos. 1, 
2 and 3; these forms were adapted and translated for use 
in the other participating countries while maintaining 
key content. The final consent forms in Brazilian-Portu-
guese, Danish, Norwegian and Swedish were translated to 
English to check for accuracy and completeness. Partic-
ipants can withdraw from the trial at any time without 
giving an explanation, and their child’s care will not be 
affected.
To reduce potential burden to families, where possible, 
trial information will be collected at visits scheduled in 
line with routine visits made to the site as part of the 
infant’s ongoing care.
randomisation
Infants meeting the eligibility criteria will be randomised 
to 6-month or 12-month surgery, corrected for gestational 
age, in a ratio 1:1 using a minimisation routine incorpo-
rating a random element to reduce predictability. Alloca-
tions will be delivered via a password-protected web-based 
system.
Every effort will be made to arrange surgery within 1 
week of the target date. However, surgery may take place 
up to 2 weeks before or 4 weeks after the target date. The 
estimated timing of surgery and the allowed time window 
for the surgery will be calculated by the online randomi-
sation system and provided to the trial site at the time of 
randomisation.
Interventions
The Sommerlad surgical technique23 will be used in all 
participants at 6 or 12 months corrected for gestational 
as determined by randomisation. This technique will be 
standardised across all surgeons, including those who 
already use the technique, by receiving direct instruc-
tion from Mr Brian Sommerlad in the operating theatre. 
Written descriptions and a video of the surgical proce-
dure will also be provided.
blinding
The nature of the interventions prevents this trial from 
being blind to participants or their carers. However, 
speech outcome assessments, at ages 12 months, 3 and 5 
years, will be rated blind to the randomly allocated group.
outcome measures
The primary endpoint for the TOPS trial is defined as 
a dichotomous outcome of whether the child has been 
perceived by the SLTs to have insufficient velopharyngeal 
function at age 5 years or not. Adequate velopharyngeal 
function is a prerequisite for normal speech produc-
tion. In children born with cleft palate, speech outcomes 
are often reported for velopharyngeal function and 
articulation.
In the presence of insufficient velopharyngeal function, 
speech will inevitably be affected by symptoms such as 
hypernasality and nasal air emission to different degrees. 
In children with isolated cleft palate, articulation disor-
ders occur less frequently than in children with complete 
cleft lip and palate. Insufficient perceived velopharyngeal 
function was therefore chosen to be the primary outcome 
and articulation outcomes as secondary outcomes. Velo-
pharyngeal insufficiency is measured by Velopharyngeal 
Composite Score (VPC) sum, which is an overall score on 
the scale 1–625. Scores ≥4 on this scale will be considered 
insufficient.
The secondary endpoints are summarised in box 1 and 
table 2 (Schedule of Assessments).
speech outcome assessments
To ensure quality of speech data, all sites will receive iden-
tical high-quality recording equipment (video recorder 
JVC-GY-HM100 series, audio recorder H4n/H5 Handy 
Table 1 Timing Of Primary Surgery for cleft palate trial 
clinical sites
Country Sites
Brazil University of São Paulo (HRAC Bauru)
Denmark Copenhagen Cleft Palate Centre, Copenhagen
Århus Speech and Hearing Institute, Århus
Norway Oslo University Hospital, Oslo
Helse Bergen HF, Bergen
Sweden Malmö University Hospital, Malmö
Gothenburg University, Gothenburg
Karolinska University Hospital,  Stockholm
University of Linköping, Linköping
Umeå University, Umeå
Uppsala University, Uppsala
UK Royal Manchester Children’s 
Hospital, Manchester
Alder Hey Children’s NHS Foundation 
Trust, Liverpool
Royal Belfast Hospital for Sick Children, Belfast
Birmingham Children’s Hospital, Birmingham
Royal Victoria Infirmary, Newcastle
University Hospitals Bristol NHS Foundation 
Trust, Bristol
Morriston Hospital, Abertawe Bro Morgannwg 
University Hospital Board, Swansea
Leeds General Infirmary, Leeds
Royal Hospital for Children, Glasgow
Royal Hospital for Sick Children, Edinburgh
Salisbury NHS Foundation Trust, Salisbury
The Children’s Hospital, John Radcliffe 
Hospital, Oxford 
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recorder and microphone Rode NT4/NT5) to be used 
at each follow-up recording according to a detailed stan-
dard operating procedure. Before data collection starts at 
each follow-up age, all SLTs will participate in a 3-day cali-
bration meeting. Afterwards, a series of video-audio prac-
tice recordings will be completed and quality checked. 
When sufficient recording quality has been reached, the 
site receives approval that they can start the trial record-
ings. To train the SLTs who are going to perform speech 
assessments, a specific procedure has been developed. 
This includes theoretical lectures on development of 
speech and language in children with cleft palate and 
methodological considerations on assessment/rating, 
and listener training with discussions and personal feed-
back. Before the assessments start, all SLTs need to pass 
a test with a specified level of intrarater and inter-rater 
reliability. They also have to pass a hearing test.
At 12 months of age, assessments will be done cross-lin-
guistically. At age 3 and 5 years, SLT rating will be confined 
to records of children sharing the SLT’s native language.
Vocalisations of 12-month-old children will be assessed 
with adjusted real-time listening, as described by Ramsdell 
et al.26 The SLTs will listen to a 45 min video recording of 
a play session between the child and the carer, divided 
into two parts (22 min each). The SLT will register every 
syllable a child produces as canonical or not, in real time, 
using a software, TimeStamper, specifically developed for 
this study.27 At the end of each recording, the SLT indi-
cates if the child babbled canonically or not and lists the 
syllables the child produced with control. In this way, the 
variables canonical babbling present, canonical babbling 
ratio and consonant inventory are obtained.
The methodology for the 5-year assessment of articula-
tion and velopharyngeal function cross-linguistically was 
developed within the Scandcleft study12 20 21 and will be 
extended to include Brazilian Portuguese. At the 5-year 
assessment, 36 target consonants from the TOPS single 
word test will be transcribed phonetically for assess-
ment of articulation and Velopharyngeal Insufficiency 
(VPI) symptoms. Target words include similar target 
sounds in the same position and with similar phonetic 
context across languages. Further, repetition of sentences 
and continuous speech are collected, as well as nasalance 
scores (Nasometer), and parent-reported intelligibility 
estimates of how well their children’s speech is under-
stood by different listeners (Intelligibility in context 
scale28). The 3-year assessment will be based on 30 of the 
36 words used in the 5-year assessment, and target conso-
nants will be transcribed phonetically for assessment of 
articulation. Error types will be classified automatically 
by a predefined script that will also allow calculation of 
percent  consonant  correct, per   cent correct place-
ment and percent correct manner. The VPC rate will be 
rated by SLTs from continuous speech both at age 3 and 
5 years.
Patient and public involvement
Parents of children with cleft palate will be approached 
by their orthodontist/surgeons prior to enrolment. 
Patients and their parents were not initially involved in 
the design of the study. However, a representative from 
the Cleft Lip & Palate Association (the charity for Cleft 
Lip & Palate in the UK) is a member of the Trial Steering 
Committee. Therefore, providing ongoing insight from 
a parent perspective with regard to the execution of this 
study and the dissemination of results.
box 1 secondary endpoints
1. Velopharyngeal function at age 5 years:
a. Velopharyngeal Composite Score summary (VPC sum).
b. Insufficient velopharyngeal function (VPC rate).
2. Velopharyngeal function at age 3 years:
a. Insufficient velopharyngeal function (VPC rate).
b. Velopharyngeal insufficiency symptoms.
3. Canonical babbling at age 12 months:
a. Canonical babbling present.
b. Canonical babbling ratio.
c. Consonant inventory.
4. Articulation at age 3 years:
a. Per cent consonants correct (PCC).
b. Per cent correct placement (PCP).
c. Per cent correct manner (PCM).
d. Non-oral consonant errors.
e. Oral consonant errors.
5. Articulation at age 5 years:
a. PCC.
b. PCP.
c. PCM.
d. Non-oral consonant errors.
e. Oral consonant errors.
6. Postoperative/long-term complications:
a. Dehiscence.
b. Infection.
c. Evidence of fistula.
7. Hearing level:
a. At 12 months:
i. Abnormal Transient Otoacoustic Emission (TEOAE).
ii. Abnormal sound-field audiometry.
b. At 3 and 5 years:
i. Abnormal pure tone audiometry in at least one ear.
ii. Abnormal pure tone audiometry in both ears.
iii. Severity of better ear (normal, mild, moderate, severe, pro-
found).
8. Middle ear function:
a. Flat line Tympanogram in at least one ear (12 months, 3 years, 
5 years).
b. Flat line Tympanogram in both ears (12 months, 3 years, 
5 years).
9. Dentofacial development at age 5 years:
a. Soft tissue ANB (the angle between soft tissue nasion, A point 
and B point on a profile photograph).32
b. Maxillary Arch Constriction score (using modified Huddart/
Bodenham scoring system).33
10. Growth at 12 months:
a. Nude weight.
b. Crown to heel length.
c. Occipitofrontal circumference.
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data collection and management
Trial data will be recorded on Case Report Forms (CRFs) 
and identifiable only by randomisation number. The data 
from completed CRFs will be entered onto the trial-spe-
cific MACRO database by the Data Manager or appropri-
ately trained personnel at the Data Coordinating Centre.
Table 2 Schedule of assessments
 Outcome measures 
Assessment schedule (age is corrected for gestational age) 
Assessments 
Postsurgery
12 months 3 years 5 years 48 hours 30 days 
Surgical complications Dehiscence √ √
Infection √ √
Evidence of fistula √ √ √
Growth Nude weight √
Crown to heel length √
Occipitofrontal circumference √
Canonical babbling Canonical babbling present* √
Canonical babbling ratio* √
Consonant inventory* √
Velopharyngeal 
function
Velopharyngeal Composite Score summary 
(VPC sum)
√†‡
Insufficient velopharyngeal function (VPC rate) √§ √¶ 
Velopharyngeal insufficiency symptoms √†
Articulation Per cent consonant correct (PCC)† √ √
Per cent correct placement (PCP)† √ √
Per cent correct manner (PCM)† √ √
Non-oral consonant errors† √ √
Oral consonant errors† √ √
Hearing level Abnormal Transient Otoacoustic Emission 
(TEOAE)
√
Abnormal soundfield audiometry √
Abnormal pure tone audiometry in at least one 
ear**
√ √
Abnormal pure tone audiometry in both ears** √ √
Severity of better ear** √ √
Soundfield audiometry** √ √
Middle ear function Flat line Tympanogram in at least one ear √ √ √
Flat line Tympanogram in both ear √ √ √
Dentofacial 
development
Soft tissue ANB†† √
Maxillary Arch Constriction score‡‡ √
Others DENVER II Developmental Assessment§§ √
Intelligibility in Context Scale Questionnaire for 
parents (ICS)
√
Local Site questionnaire¶¶ √ √
Sources of speech assessments:
* Video of play interaction. 
†TOPS picture naming test.
‡Nine-word string.
§Spontaneous speech.
 ¶:Spontaneous speech(retelling of bus story).
**If pure tone audiometry could not be performed, then soundfield audiometry will be performed.
††The angle between soft tissue nasion A point and B point on a profile photograph.
‡‡Maxillary Arch Constriction score is determined using modified Huddart/Bodenham scoring system.
§§DENVER II Developmental Assessment is carried out at the time of surgery.
 ¶¶ Local site questionnaire sent to local speech and language therapists outside TOPS research team to collect data on direct and indirect 
therapy given to the child in the intervals between assessment visits.
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Video and audio recording
Once recorded, video and audio recordings will be saved 
onto encrypted USB drives. They will be posted to the 
Data Coordinating Centre where, on receipt, they will be 
logged and stored onto the trial-specific secure server. 
This server will be backed up once a day to ensure data 
are not lost once received. Recordings are quality checked 
by the Core Speech Group and/or the Trial Administra-
tive Centre. A satisfactory recording is one that passes 
prespecified quality checks on lighting, length and sound. 
Quality checks will be performed regularly and feedback 
to site will be provided on their suitability for assessment.
Maxillary arch impressions
Maxillary arch impressions will be obtained at the time 
of surgery to provide a mould for plaster casts, which are 
sent to the TOPS Administrative Centre at the University 
of Manchester.
In addition, impressions of the maxillary and mandib-
ular dental arches will be obtained at the 5-year follow-up 
appointment. Impressions are taken by a designated 
member of staff (usually the orthodontist) using appro-
priate impression material. The occlusion will be regis-
tered with a wax wafer in the position of maximal 
intercuspation. The study models made from the impres-
sions will be stored at the TOPS Administrative Centre.
Photographs
Intraoral photographs will be taken at the time of surgery, 
and frontal and lateral photographs will be obtained at 
the 5-year visit. The photographs will be saved onto 
encrypted USBs, on receipt by the Data Coordinating 
Centre they will be logged and stored onto trial-specific 
secure hard drives.
statistical analysis and sample size considerations
Proposed sample size
Three hundred  patients per arm will allow a reduction in 
insufficient velopharyngeal function at 5 years from 40% 
to 29% to be detected with 81% power using a chi-square 
test (two-sided significance test at 0.05 level). The esti-
mate of 40% was obtained from a pilot trial of 50 patients 
of 5 years of age, collected during the planning period for 
this grant application.12 To allow an approximate drop 
out of 10%, 648 participants will be recruited. However, 
to consider the potential impact of variability around the 
value of 40%, 300 patients per group would provide 80% 
power to detect a reduction from 30% to 20% and 76% 
power to detect a reduction from 20% to 12%.
The trial enrolment, allocation, follow-up and analysis 
will be reported using the ‘Consolidated Standard of 
Reporting Trials' (‘CONSORT’)29 and the International 
Conference on Harmonisation E9 guidelines.30 A full and 
detailed statistical analysis plan31 will be developed prior 
to the final analysis of the trial. The main features of the 
statistical analysis plan are included here.
The primary analysis will be by intention-to-treat 
principle, as far as is practically possible using a 5% 
significance level throughout. Rather than adjust for 
multiplicity of secondary outcomes, relevant results from 
other studies already reported in the literature will be 
taken into account in the interpretation. The approach 
to formal analyses will be dependent on outcome type as 
follows:
 ► Dichotomous outcome will be compared between the two 
groups using a chi-squared test and the effect estimate 
will be reported in terms of the relative risk and 95% 
confidence  interval.
 ► Short ordinal outcomes will be compared using a 
chi-squared test for trend.
 ► Continuous and long ordinal outcomes will be compared 
between the two groups using a two group t-test. The 
difference in means will be presented with a 95% CI.
Baseline and operative characteristics and safety data 
will be presented using descriptive statistics only.
If the percentage of major protocol deviations exceeds 
10% and the trial management group consider this anal-
ysis appropriate, a per-protocol analysis in which prespec-
ified major protocol deviations indicate exclusion of a 
participant from the analysis set will be conducted.
trial oversight and monitoring
The Trial Management Group (TMG), Trial Steering 
Committee (TSC) and Data Safety and Monitoring Board 
(DSMB) will provide ongoing oversight and will monitor 
accruing trial data. The roles, responsibilities and compo-
sition of each of these committees are provided in online 
supplementary material no. 4. A risk assessment has been 
conducted and used to inform a trial-specific monitoring 
plan agreed by the independent oversight committees.
trial status and timeline
The overall programme commenced on 13 July 2010. 
Applications for ethics approval were submitted on 10 
November 2009. Recruitment to the trial commenced on 
13 July 2010. Participants will be followed up until 30 July 
2020.
This trial completed recruitment on 21 July 2015, and 
the last patient is due to attend their last visit until 30 of 
July 2020.
EthICs
Ethical approval has been sought in each participating 
country according to country-specific procedures. The 
protocol has gained favourable opinion from the Multi-
centre Research Ethics Committee in the UK and from 
relevant ethics committees for each participating centre. 
TOPS Protocol Version 1.1 (of 2 November 2009) was 
approved by UK ethics on 8 January 2010, the Protocol 
Version 4.0 (of 26 August 2015) was approved by UK 
ethics on 1 October 2015 and the Protocol Version 5.0 
(of 22 August 2018) was approved by UK ethics on 18 
November 2018. A summary of substantial protocol 
amendments and relevant ethics committees is provided 
in online supplementary material no. 5.
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dissemination
Following completion of the study, the principal investi-
gator is expected to publish the results of this research in 
a peer-reviewed scientific journal. According to the NIH 
Public Access Policy, all journal articles arising from this 
NIH-funded trial will be submitted to the digital archive 
PubMed Central. Trial investigators have the right and 
responsibility to communicate their findings to the scien-
tific community and to the public. Findings of the trial 
will also be presented at National and International meet-
ings of relevant professional bodies and research groups. 
Reports will also be posted on the WHO website ( www. 
who. org) craniofacial section. Access to clinical data sets 
within speech, genetic, surgical and other fields will be 
available to others following the acceptance for publica-
tion of the main findings from the final dataset. Requests 
to access data will be subject to participant confidentiality 
concerns and to contemporary NIH guidance on data-
sharing plans.
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